22:35 , Jun 25, 2018 |  BC Extra  |  Company News

Management tracks: Nordic Nanovector, Molecular Partners

Cancer company Nordic Nanovector ASA (OSE:NANO) hired Eduardo Bravo as CEO, effective July 2. He was CEO at TiGenix N.V. (NASDAQ:TIG; Euronext:TIG). Protein therapeutics company Molecular Partners AG (SIX:MOLN) said CSO Michael Stumpp has become...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Company News

Biotronik sales and marketing update

Biotronik launched 35 and 40 mm versions of its Orsiro Hybrid Drug-Eluting Stent in countries that recognize CE Mark approval to treat coronary artery stenosis. The product is a BIOlute-coated stent using a limus drug...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Passeo-18 Lux update

Biotronik completed enrollment of 60 patients in the single-blind, European BIOLUX P-I trial comparing Passeo-18 Lux vs. an uncoated balloon catheter. Biotronik SE & Co. KG , Berlin, Germany   Product: Passeo-18 Lux   Business:...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Clinical News

Orsiro Hybrid Drug-Eluting Stent: Phase IV started

Biotronik began the open-label European Phase IV BIOFLOW-II trial in about 440 patients to compare its Orsiro Hybrid Drug-Eluting Stent vs. Xience Prime from Abbott Laboratories (NYSE:ABT, Abbott Park, Ill.). Orsiro received CE Mark approval...
07:00 , May 31, 2004 |  BC Week In Review  |  Company News

Biotronik AG, Conor Medsystems deal

The companies partnered to develop a bioabsorbable drug-eluting stent. The deal combines Biotronik's absorbable metal stent with Conor's reservoirs that hold therapeutics inside stents. Separately, Biotronik received worldwide distribution rights to Conor's Costar cobalt chromium...
08:00 , Feb 23, 2004 |  BioCentury  |  Emerging Company Profile

Avontec: Trick or treat

Many diseases are caused by sets of genes being activated at the wrong time. Avontec GmbH thinks it can influence the activity of several genes simultaneously by inhibiting proteins that control the expression of multiple...
08:00 , Feb 23, 2004 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Avontec GmbH Martinsried, Germany Technology: Decoy oligodeoxynucleotide (decoy-ODN) technology Disease focus: Cardiovascular and inflammatory diseases Clinical status: Phase IIa Founded: 2001 by Gerd Hasenfuss and Markus Hecker Corporate partners: Biotronik GmbH & Co. KG University...